IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today
announced its preliminary unaudited revenue for the full year
2021. Total revenue for 2021 is expected to be in the range of
$17.0 to $17.2 million, representing an increase of approximately
64% to 66% compared to $10.4 million for the full year 2020.
Since the commercial launch in 2018, Isoplexis
has placed 209 total instruments, including 98 new instruments sold
during 2021. As of year end, IsoPlexis passed an important
milestone with 67% of US comprehensive cancer centers and in
addition, 100% of the top 15 pharma now using IsoPlexis for
functional cell analysis.
IsoPlexis also today unveiled The Superhuman
Cell Library, an industry-first mapping of the proteomically driven
cells, unique to IsoPlexis’ platform, that determine how the human
body responds to complex disease. By identifying a comprehensive
range of rare but important super cells, the library categorizes
how these cells have been used to predict patient response to
therapies in a wide range of clinically relevant journals. The
library also lays the groundwork for customers to continue to add
on to the characterization of these uniquely predictive cells to
advance all of human health.
“Our 2021 revenue growth reinforces the value of
our platform and how, together with the release of The Superhuman
Cell Library, IsoPlexis is taking a lead in advancing the future of
medicine and health,” said IsoPlexis Chief Executive Officer Sean
Mackay. “The IsoPlexis platform allows researchers to uncover
superhero cells and superhuman biology for the first time,
unlocking unprecedented insights into the development of therapies
for the world’s toughest diseases.”
These preliminary results are based on
management’s initial analysis of operations for the quarter that
ended on December 31, 2021. The company expects to issue full
financial results for the fourth quarter and full year 2021 in late
February 2022.
The Superhuman Cell Library provides a
comprehensive definition of proteomically driven cells that is
leading to major advances in the way illnesses are diagnosed and
treated. It is a valuable resource across oncology, immunology,
infectious diseases, neurology, inflammatory diseases, and cell and
gene therapies. It is available now as an industry-wide,
literature-referenced, and consistently updated resource at
http://isoplexis.com/FCL.
“Following the releases of the Human Cell Atlas
and the Human Genome Atlas, definitions of the functional proteome
from each cell are critical to moving forward our understanding of
human cell behavior. By mapping our body’s most functionally active
immune cells, or cell “superheroes”, IsoPlexis is making a key
contribution to furthering our understanding of the power of each
single cell in the human body,” said James R. Heath Ph.D. Dr. Heath
is President and Professor at the Institute for Systems Biology in
Seattle, and a Professor of Bioengineering at the University of
Washington. He also co-founded and is a member of the IsoPlexis
scientific advisory board.
About IsoPlexisIsoPlexis is the
Superhuman Cell company.
IsoPlexis’ systems uniquely identify a
comprehensive range of multifunctional single cells, i.e. the
superhero cells in the human body. These cells enable researchers
to understand and predict disease progression, treatment resistance
and therapeutic efficacy to advance all of human health.
IsoPlexis has been named Top Innovation or
Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot
and multiple others. The IsoPlexis platform is used globally by
researchers, including those at the top 15 global pharmaceutical
companies and at two-thirds of leading U.S. comprehensive cancer
centers.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
“forward-looking statements.” These statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies
and other future conditions. Such forward-looking statements may
include, without limitation, statements about future opportunities
for us and our products and services, our future operations,
financial or operating results, including our financial guidance,
anticipated business levels, future earnings, planned activities,
anticipated growth, market opportunities, strategies, competitions
and other expectations and targets for future periods. In some
cases, you can identify forward-looking statements because they
contain words such as “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “may,” “predict,” “project,” “target,”
“potential,” “seek,” “will,” “would,” “could,” “should,”
“continue,” “contemplate,” “plan,” and other words and terms of
similar meaning. Forward-looking statements are subject to known
and unknown risks and uncertainties, many of which may be beyond
our control. We caution you that forward-looking statements are not
guarantees of future performance or outcomes and that actual
performance and outcomes may differ materially from those made in
or suggested by the forward-looking statements contained in this
press release. In addition, even if our results of operations,
financial condition and cash flows, and the development of the
markets in which we operate, are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in subsequent periods. New factors emerge from time to
time that may cause our business not to develop as we expect, and
it is not possible for us to predict all of them.
Factors that could cause actual results and
outcomes to differ from those reflected in forward-looking
statements include, among others, the following: estimates of our
addressable market, market growth, future revenue, expenses,
capital requirements and our needs for additional financing; the
implementation of our business model and strategic plans for our
products and technologies; competitive companies and technologies
and our industry; our ability to manage and grow our business by
expanding our sales to existing customers or introducing our
products to new customers; our ability to develop and commercialize
new products; our ability to establish and maintain intellectual
property protection for our products or avoid or defend claims of
infringement; the performance of third party suppliers; our ability
to hire and retain key personnel and to manage our future growth
effectively; our ability to obtain additional financing in future
offerings; the volatility of the trading price of our common stock;
our expectations regarding use of proceeds from our initial public
offering (“IPO”); the potential effects of government regulation;
the impact of COVID-19 on our business; and our expectations about
market trends. For a further discussion of these and other factors
that could impact our future results, performance or transactions,
see the section “Risk Factors” included in our Form 10-Q filed with
the Securities and Exchange Commission (“SEC”) on November 12,
2021, and our other filings with the SEC. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. It is not possible for us to predict
all risks, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statements we may make. We qualify
all of the forward-looking statements in this press release by
these cautionary statements. Except as required by law, we
undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor
Contactinvestors@isoplexis.com
Press
Contactpress@isoplexis.com
Related
Linkswww.isoplexis.com
SOURCE IsoPlexis
IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
From Jun 2024 to Jul 2024
IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
From Jul 2023 to Jul 2024